Sürdürülebilir Kalkınma Amaçları
Yazarlar
- Acar, Caner(1)
- Aytac, Ali(1)
- Biter, Sedat(1)
- Coskun, Alper(1)
- Demir, Teyfik(1)
- Demirciler, Erkut(1)
- Dilek, Mehmet siddik(1)
- Disli, Ahmet Kursat(1)
- Goker, Erdem(1)
- Gürsoy, Pinar(1)
- Kara, Mahmut(1)
- Kolkiran, Nagihan(1)
- Koseci, Tolga(1)
- Kus, Fatih(1)
- Majidova, Nargiz(1)
- Menekse, Serkan(1)
- Orman, Seval(1)
- Ozveren, Ahmet(1)
- Sahbazlar, Mustafa(1)
- Sahin, Goekhan(1)
- Sevinc, Alper(1)
- Seyyar, Mustafa(1)
- Tünbekici, Salih(1)
- Unsal, Ahmet(1)
- Yucel, Hakan(1)
- Yuksel, Haydar cagatay(1)
Yayınlar
- MakaleAçık Erişim2025Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study
Tünbekici, Salih; Yuksel, Haydar cagatay; Acar, Caner; Sahin, Goekhan; Orman, Seval; Majidova, Nargiz; Coskun, Alper; Seyyar, Mustafa; Dilek, Mehmet siddik; Kara, Mahmut
Background/Objectives: In the REGOMA trial, regorafenib demonstrated an overall survival advantage over lomustine, and it has become a recommended treatment for recurrent glioblastoma in guidelines. This study aimed to evaluate the effectiveness and safety of regorafenib as a third-line treatment for patients with recurrent glioblastoma who progressed while taking bevacizumab-based therapy. Methods: This retrospective, multicenter study in Turkey included 65 patients treated between 2021 and 2023 across 19 oncology centers. The main inclusion criteria were histologically confirmed isocitrate dehydrogenase (IDH)-wildtype glioblastoma, progression after second-line bevacizumab-based treatment, and an Eastern Cooperative Oncology Group (ECOG) performance status score of <= 2. Patients received regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle. Results: The median age of the patients was 53 years (18-67 years), with a median progression-free survival of 2.5 months (95% Confidence Interval: 2.23-2.75) and a median overall survival of 4.1 months (95% CI: 3.52-4.68). The median overall survival was improved in patients who received subsequent therapy after regorafenib treatment compared with those who did not (p = 0.022). Progression-free survival was longer in patients with ECOG 0-1 than in those with ECOG 2 (p = 0.042). The safety profile was consistent with that of the REGOMA trial, with no drug-related deaths observed. Conclusions: Regorafenib shows good efficacy and safety as a third-line treatment for recurrent glioblastoma after bevacizumab-based therapy. This study supports the use of regorafenib and emphasizes the need for further randomized studies to validate its role and optimize treatment strategies.